Pharma execs testify in front of Senate of rising drug prices

pharmafile | February 27, 2019 | News story | Research and Development Business, Senate hearing, USA, pharma, sfc 

Senior Executives from seven major pharmaceutical companies, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi and Johnson & Johnson appeared before the US Senate Finance Committee (SFC) on Tuesday to testify on the high prices of drugs in the United States.

The hearing comes as both parties place focus on the rising price of drugs. Committee chairman Chuck Grassley was open in stating that “there is no question that researchers and doctors have developed treatments and cures for diseases where there were once none, and such innovations take time and money.”

However the Senator suggested that “there is a balance between incentivising innovation and keeping prices affordable for consumers and taxpayers.”

Before the hearing Grassley tweeted “I hope the drug co CEOs testifying tmrw don’t try to blame everyone but themselves/take no responsibility for their role in fixing the problem We already understand there are other factors to consider Tmrw is abt the part drug cos can do to lower costs for patients+taxpayers.”

Nevertheless the pharma executives did seek to shift the blame as they continued to accuse pharmacy benefit managers (PBMs) and insurers of being responsible for high drug prices.

Meanwhile the execs presented various proposals aimed at addressing the problem, including offering incentives to increase the use of generics and greater financial aid for patients.

Despite the scrutiny, little concrete came out of the hearing. As noted by Sen. Ron Wyden (Ore.), the Senate Finance Committee’s top Democrat: “I’ve heard a lot of happy talk this morning. But what people are taking away from this hearing … well, no firm commitments have been made to lower list prices.”

For the most part the pharma executives were able to avoid being pinned. Notably, when asked whether they had blocked generic drugmaker’s access to drug samples all seven pharma chiefs said that they hadn’t. However Pfizer and AstraZeneca have both been accused of doing so by the FDA.

Louis Goss

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content